Core Viewpoint - The company has signed an investment agreement to acquire a stake in Swiss aesthetic company Suisselle SA, enhancing its strategic relationship and expanding its presence in the global aesthetic market [1][2] Group 1: Investment Details - The investment in Suisselle will allow the company to permanently hold exclusive agency rights for the CELLBOOSTER product in China, strengthening long-term collaboration [1] - The partnership will leverage Suisselle's established platform in Europe to accelerate the promotion and sales of the company's self-developed aesthetic products in European and other overseas markets [1] Group 2: Strategic Expansion - The investment marks a significant step in the company's global strategy for the aesthetic business, completing its strategic layout in the core aesthetic markets of Europe and North America [2] - The company aims to continue driving high-quality aesthetic solutions through a combination of independent research and international collaboration, creating long-term sustainable value for shareholders and investors [2]

智通财经APP讯，四环医药(00460)发布公告，本集团于2025年9月对瑞士医美公司Suisselle SA(Suisselle) 进行投资入股，双方已正式签署投资认购协议。此次合作将提升本集团与Suisselle的战略关系，共同拓 展全球医美市场。 本集团早在2022年已获得CELLBOOSTER水光针在中国地区的独家代理权，本次投资入股将进一步强 化双方长期合作关系。通过本次投资入股，本集团将永久享有CELLBOOSTER水光针产品的独家代理 权益，并深度参与其运营与发展。 此外，本次四环医药投资入股Suisselle后，双方将合作通过Suisselle在欧洲的成熟平台，加速本集团旗 下"渼颜空间"自研医美产品在欧洲及其他海外市场的推广与销售。同时，本集团将持续引入Suisselle及 其他欧洲创新产品，丰富国内医美产品矩阵。这一布局与本集团全球化战略高度契合，旨在构建覆盖研 发、生产与销售的国际化医美生态体系。 近年来，本集团积极推进医美业务全球化战略，于2021年全资收购美国医疗美容器械公司Genesis Biosystems，成功切入北美市场。此次投资Suisselle，是本集团医美产业全球化战略 ...